-
In community-dwelling women age 70 years and older, annual oral administration of high-dose vitamin D for 3-5 years resulted in a higher, not lower, incidence of falls and fractures.
-
Because it is recognized that type 2 diabetics (DM2) incur greater risk of CV outcomes than the general population, consensus groups have advocated BP < 130/80 mmHg as a preferred goal, in contrast to 140/90 mmHg for the general hypertensive population.
-
The ECG shown above was obtained from an 88-year-old woman who refused treatment. What is the rhythm? Is there a grouping? Is anything else going on?
-
New reports about proton pump inhibitors and the effects of gastric suppression, pioglitazone vs vitamin E for non-alcoholic steatohepatitis, metformin and vitamin B12 deficiency, and FDA Actions.
-
Although some aspects of vaginal birth after cesarean delivery (VBAC) have been covered in previous OB/GYN Clinical Alert issues, I cannot pass up an opportunity to comment on two papers appearing in the June issue of Obstetrics & Gynecology.
-
Carcinosarcoma of the uterus is a rare condition accounting for less that 4% of all uterine neoplasms. Previous work has identified that the most active single agents are platinum, ifosfamide, paclitaxel, and doxorubicin.
-
Without fanfare, the FDA approved oral tranexamic acid tablets (Lysteda), the first non-hormonal product cleared to treat heavy menstrual bleeding in the United States.
-
In this issue: Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
-
-
I love this article. It's relevant to our daily practice, but, more importantly, it verbalizes the same issues that both physicians and patients want clarified.
